Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Oncorus Inc (ONCR)

Oncorus Inc (ONCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates Globe Newswire - Thu Aug 4, 2022

Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022Company remains on track...

ONCR : 0.1260 (-3.08%)
Oncorus Appoints Douglas Fambrough to Board of Directors Globe Newswire - Thu Jun 23, 2022

-Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 ...

ONCR : 0.1260 (-3.08%)
Oncorus to Present at the Jefferies Global Healthcare Conference Globe Newswire - Wed Jun 1, 2022

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...

ONCR : 0.1260 (-3.08%)
Chameleon Biosciences Appoints Silicon Valley Scientist and Entrepreneur, Dr. Thomas Chalberg, to Board Position ACCESS Newswire - Wed Jan 5, 2022

BERKELEY, CA / ACCESSWIRE / January 5, 2022 / Chameleon Biosciences Inc., a company developing the EVADERTM platform to produce next-generation gene therapies that are more potent and less immunogenic,...

ONCR : 0.1260 (-3.08%)
DPS Group Tapped by Oncorus to Design GMP Clinical Manufacturing Facility ACCESS Newswire - Wed Sep 22, 2021

Clinical stage biopharmaceutical company focused on viral immunotherapies building out state-of-the-art, 88,000 square foot facility in Massachusetts BOSTON, MA / ACCESSWIRE / September 22, 2021 / DPS...

ONCR : 0.1260 (-3.08%)

Barchart Exclusives

Dear Oklo Stock Fans, Mark Your Calendars for July 4 Barchart - 48 minutes ago
Investors dumped OKLO after its quarterly report recently. But Wall Street knows July 4 could be the real fireworks show for this next-generation nuclear bet. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.